Walleye Capital LLC Takes Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Walleye Capital LLC purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, Holdings Channel.com reports. The fund purchased 72,009 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,981,000.

A number of other hedge funds have also recently modified their holdings of the business. XTX Topco Ltd purchased a new position in ANI Pharmaceuticals in the 4th quarter worth about $997,000. Barclays PLC lifted its position in ANI Pharmaceuticals by 9.8% during the fourth quarter. Barclays PLC now owns 157,060 shares of the specialty pharmaceutical company’s stock valued at $8,682,000 after acquiring an additional 14,027 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth $3,916,000. Legal & General Group Plc grew its stake in shares of ANI Pharmaceuticals by 5.6% during the fourth quarter. Legal & General Group Plc now owns 48,425 shares of the specialty pharmaceutical company’s stock worth $2,677,000 after acquiring an additional 2,585 shares during the last quarter. Finally, Bank of Montreal Can grew its position in ANI Pharmaceuticals by 3.7% during the 4th quarter. Bank of Montreal Can now owns 230,153 shares of the specialty pharmaceutical company’s stock worth $12,723,000 after purchasing an additional 8,257 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $197,792 over the last 90 days. 12.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim reissued a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Trading Down 0.5 %

Shares of ANI Pharmaceuticals stock opened at $69.20 on Thursday. The stock has a 50 day moving average of $62.88 and a 200 day moving average of $59.29. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -125.82 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.18.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.